SCHEMBL17501656

SCHEMBL17501656

COc1ccc2[nH]c(=O)n(CCCCO)c(=O)c2c1Cc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TRPC5 Q9UL62 4/20 0.63
ALDH1A1 P00352 3/20 0.46
HPGD P15428 3/20 0.46
KDM4E B2RXH2 5/20 0.43
HSD17B10 Q99714 4/20 0.43
KMT2A Q03164 1/20 0.43
MAPT P10636 3/20 0.41
LMNA P02545 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
HTR7 P34969 3/20 0.41
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
MAPK10 P53779 1/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17517369 0.97 TRPC5 (0.67) TRPC5ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL17501699 0.88 TRPC5 (0.67) TRPC5ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL17522760 0.83 TRPC5 (0.55) TRPC5ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL17501696 0.81 TRPC5 (0.94) TRPC5ALDH1A1HPGDKDM4ELMNA
SCHEMBL20752037 0.79 TRPC5 (0.53) TRPC5ALDH1A1HPGDKDM4EKMT2A
SCHEMBL20752038 0.78 TRPC5 (0.68) TRPC5ALDH1A1HPGDMAPTNPSR1
SCHEMBL17517368 0.77 TRPC5 (1.00) TRPC5
SCHEMBL20752039 0.76 TRPC5 (0.53) TRPC5ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL20752030 0.76 TRPC5 (0.53) TRPC5ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL17522758 0.75 TRPC5 (0.45) TRPC5ALDH1A1HPGDKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3180318-B1 QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS HYDRA BIOSCIENCES INC (US) 2019-02-20 EP disclosed
US-9745272-B2 Quinazoline-2,4(1 H,3H)-dione derivatives HYDRA BIOSCIENCES, INC. (US) 2017-08-29 US disclosed
EP-3180318-A1 QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS Hydra Biosciences, Inc. (US) 2017-06-21 EP disclosed
WO-2016023826-A1 QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS HYDRA BIOSCIENCES, INC. (US) 2016-02-18 WO disclosed
US-20160039772-A1 QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039772-A1 QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES TRPC5, HTR5A, TRPV5 TRPC5 1/4885ALDH1A1 1768/4885HPGD 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.